Aspira Women’s Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 12
Aspira Women's Health Inc. (Nasdaq: AWH), a bio-analytical women's health company focusing on gynecologic disease diagnostic tools, has announced its plans to report second quarter 2024 financial results on Monday, August 12, 2024. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the financial results and provide a corporate update.
Investors and interested parties can access the conference call toll-free at 877-407-4018. A webcast of the call will be available, and a replay will be accessible on the Events & Presentation page of Aspira Women's Health's Investor Relations website.
Aspira Women's Health Inc. (Nasdaq: AWH), un'azienda bio-analitica nel settore della salute femminile specializzata in strumenti diagnostici per malattie ginecologiche, ha annunciato i suoi piani di comunicare i risultati finanziari del secondo trimestre 2024 il lunedì 12 agosto 2024. L'azienda terrà una conferenza telefonica e un webcast alle 16:30 ora orientale nello stesso giorno per discutere i risultati finanziari e fornire un aggiornamento aziendale.
Gli investitori e le parti interessate possono accedere alla conferenza telefonica senza costi al numero 877-407-4018. Un webcast della chiamata sarà disponibile, e una registrazione sarà accessibile nella pagina Eventi e Presentazioni del sito web delle Relazioni con gli Investitori di Aspira Women's Health.
Aspira Women's Health Inc. (Nasdaq: AWH), una empresa bioanalítica enfocada en la salud femenina que se especializa en herramientas de diagnóstico de enfermedades ginecológicas, ha anunciado sus planes para reportar resultados financieros del segundo trimestre de 2024 el lunes 12 de agosto de 2024. La empresa llevará a cabo una llamada de conferencia y un webcast a las 4:30 p.m. hora del Este el mismo día para discutir los resultados financieros y proporcionar una actualización corporativa.
Los inversionistas y partes interesadas pueden acceder a la llamada de conferencia sin costo al 877-407-4018. Se dispondrá de un webcast de la llamada, y una repetición estará accesible en la página de Eventos y Presentaciones del sitio web de Relaciones con Inversionistas de Aspira Women's Health.
Aspira Women's Health Inc. (Nasdaq: AWH), 부인과 질병 진단 도구에 중점을 둔 생물 분석 여성 건강 회사는 2024년 2분기 재무 결과를 2024년 8월 12일 월요일에 발표할 계획을 발표했습니다. 회사는 같은 날 동부 표준시 오후 4시 30분에 재무 결과를 논의하고 기업 업데이트를 제공하기 위해 컨퍼런스 콜 및 웹캐스트를 개최할 것입니다.
투자자 및 관심 있는 당사자는 877-407-4018로 무료로 컨퍼런스 콜에 접속할 수 있습니다. 통화의 웹캐스트가 제공될 예정이며, 재생은 Aspira Women's Health의 투자자 관계 웹사이트의 이벤트 및 프레젠테이션 페이지에서 확인할 수 있습니다.
Aspira Women's Health Inc. (Nasdaq: AWH), une entreprise bio-analytiques spécialisée dans la santé des femmes et les outils de diagnostic des maladies gynécologiques, a annoncé ses projets de publier les résultats financiers du deuxième trimestre 2024 le lundi 12 août 2024. L'entreprise organisera une conférence téléphonique et un webcast à 16 h 30, heure de l'Est le même jour pour discuter des résultats financiers et fournir une mise à jour de l'entreprise.
Les investisseurs et les parties intéressées peuvent accéder à la conférence téléphonique sans frais au numéro 877-407-4018. Un webcast de l'appel sera disponible, et un enregistrement sera accessible sur la page Événements et Présentations du site des Relations avec les Investisseurs d'Aspira Women's Health.
Aspira Women's Health Inc. (Nasdaq: AWH), ein bioanalytisches Unternehmen für Frauengesundheit, das sich auf diagnostische Werkzeuge für gynäkologische Krankheiten spezialisiert hat, hat seine Pläne bekannt gegeben, die Finanzergebnisse für das zweite Quartal 2024 am Montag, den 12. August 2024 bekannt zu geben. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz und Webcast abhalten, um die Finanzergebnisse zu besprechen und ein Unternehmensupdate zu geben.
Investoren und Interessierte können die Telefonkonferenz gebührenfrei unter 877-407-4018 erreichen. Ein Webcast der Konferenz wird verfügbar sein, und eine Aufzeichnung wird auf der Seite Veranstaltungen & Präsentationen der Website für Investor Relations von Aspira Women's Health zugänglich sein.
- None.
- None.
AUSTIN, Texas, July 31, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended June 30, 2024, on Monday, August 12, 2024. Management will also host a conference call at 4:30 p.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows:
| Conference Call & Webcast Details: | |
| Date: | Monday, August 12, 2024 |
| Time: | 4:30 p.m. ET |
| Toll Free: | 877-407-4018 |
| Webcast: | Click HERE |
A replay of the webcast will also be available on the Events & Presentation page of the Aspira Women’s Health Investor Relations website.
About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.
OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of
Our in-development test pipeline is designed to expand our ovarian cancer portfolio and addresses the tremendous need for noninvasive diagnostics for endometriosis, a debilitating disease that impacts millions of women worldwide. In ovarian cancer, our OvaMDxSM risk assessment is designed to combine microRNA and protein biomarkers with patient data to further enhance the sensitivity and specificity of our current tests. In endometriosis, EndoCheckSM is the first-ever noninvasive test designed to identify endometriomas, one of the most commonly occurring forms of endometriosis. The EndoMDxSM test is designed to combine microRNA and protein biomarkers with patient data to identify all endometriosis.
Investor Relations Contact:
Nicole Sandford
Chief Executive Officer
Investors@aspirawh.com
FAQ
When will Aspira Women's Health (AWH) release its Q2 2024 earnings?
What time is Aspira Women's Health's (AWH) Q2 2024 earnings call?
How can I access Aspira Women's Health's (AWH) Q2 2024 earnings call?
Will there be a replay available for Aspira Women's Health's (AWH) Q2 2024 earnings call?
